title: Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma.
abstract: BACKGROUND
  Measurement of sputum or blood eosinophils may allow identification of a severe eosinophilic asthma population responsive to mepolizumab.
  
  
  OBJECTIVE
  The primary objective was assessment of a single blood eosinophil measurement to predict future eosinophil measurements in the following year versus using multiple blood eosinophil measurements. In addition, we examined whether a single sputum or blood eosinophil measurement was a useful biomarker for predicting treatment response to mepolizumab.
  
  
  METHODS
  Based on data from placebo subjects (n = 155), we determined whether a blood eosinophil count of 150/μl or greater at screening remained on average above this level during the following year. The rate of exacerbation reduction in the sputum substudy population based on the screening blood eosinophil count and sputum eosinophils was evaluated.
  
  
  RESULTS
  Of 115 patients with eosinophils 150/μl or greater at screening, 98 (85%) remained above this level in their post-screening average. Using the average of two, three or four measurements 150/μl or greater, 97 (85%), 103 (90%), and 105 (92%) have postscreening averages above 150/μl. Mepolizumab reduced exacerbations by 69% (95% confidence interval [CI] = 41-83%) in subjects with baseline sputum eosinophils of 3% or greater compared with 66% (95% CI = 7-87%) in subjects with baseline sputum eosinophils under 3%. The reduction was 72% (95% CI = 41-83%) in subjects with blood eosinophils of 150/μl or greater compared with 30% (95% CI = -134 to 79%) in subjects with blood eosinophils under 150/μl.
  
  
  CONCLUSIONS
  A single measurement of 150/μl or greater predicted the average of subsequent measurements being 150/μl or greater in 85% of this population. Using an average of multiple measurements only marginally increases the sensitivity. Sputum eosinophils did not predict treatment response with mepolizumab.
authors.affiliation: 1 Respiratory Therapeutic Unit, GlaxoSmithKline, Research Triangle Park, North Carolina.
authors.forename: Lynn E
authors.initials: LE
authors.lastname: Katz
authors.forename: Gerald J
authors.initials: GJ
authors.lastname: Gleich
authors.forename: Benjamin F
authors.initials: BF
authors.lastname: Hartley
authors.forename: Steven W
authors.initials: SW
authors.lastname: Yancey
authors.forename: Hector G
authors.initials: HG
authors.lastname: Ortega
mesh_terms: D000328:Adult; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D001249:Asthma / Q000097:blood* / Q000188:drug therapy / Q000276:immunology; D018450:Disease Progression; D004802:Eosinophilia / Q000097:blood* / Q000188:drug therapy / Q000276:immunology; D004804:Eosinophils / Q000166:cytology* / Q000276:immunology; D005260:Female; D006801:Humans; D015848:Interleukin-5 / Q000037:antagonists & inhibitors; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012720:Severity of Illness Index; D013183:Sputum / Q000166:cytology*; D016896:Treatment Outcome
chemical_list: D018927:Anti-Asthmatic Agents; D061067:Antibodies, Monoclonal, Humanized; D015848:Interleukin-5; C434107:mepolizumab